Partial Seizure is an indication for drug development with over 20 pipeline drugs currently active. According to GlobalData, preregistered drugs for Partial Seizure have a 91.67% likelihood of approval (LoA) indication benchmark. GlobalData’s report assesses how phase transition success rate (PTSR) and likelihood of approval (LoA) scores for pipeline drugs in Partial Seizure compared to historical benchmarks. Buy the report here.
Smarter leaders trust GlobalData
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Partial Seizure overview
Focal onset seizures, or partial seizures, are prevalent neurological disorders marked by abnormal electrical activity in specific brain regions. Manifesting in diverse forms, symptoms range from subtle sensory disruptions to noticeable motor movements and altered consciousness. Precise diagnosis relies on clinical evaluation, neuroimaging, and electroencephalography. Managing focal onset seizures involves a range of strategies, including antiepileptic medications, surgical interventions, and lifestyle adjustments.
For a complete picture of PTSR and LoA scores for drugs in Partial Seizure, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
